UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 189

Sortiert nach

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells

Frontiers in immunology, 2023-01, Vol.13, p.1102471-1102471

2023

Volltextzugriff (PDF)

CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1

Scientific reports, 2021-10, Vol.11 (1), p.21230-21230, Article 21230

2021

Volltextzugriff (PDF)

Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?

Frontiers in immunology, 2023, Vol.14, p.1167443-1167443

2023

Volltextzugriff (PDF)

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells

Frontiers in immunology, 2018-06, Vol.9, p.1246-1246

2018

Volltextzugriff (PDF)

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

Frontiers in immunology, 2018-06, Vol.9, p.1492-1492

2018

Volltextzugriff (PDF)

Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment

Medicina (Kaunas, Lithuania), 2021-10, Vol.57 (10), p.1104

2021

Volltextzugriff (PDF)

Molecular dynamics of targeting CD38 in multiple myeloma

British journal of haematology, 2021-05, Vol.193 (3), p.581-591

2021

Volltextzugriff (PDF)

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer

Journal of experimental & clinical cancer research, 2018-11, Vol.37 (1), p.286-286, Article 286

2018

Volltextzugriff (PDF)

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications

Clinical and applied thrombosis/hemostasis, 2022, Vol.28, p.107602962211257-10760296221125785

2022

Volltextzugriff (PDF)

Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells

PloS one, 2013-04, Vol.8 (4), p.e60975

2013

Volltextzugriff (PDF)

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models

Molecular oncology, 2024-06, Vol.18 (6), p.1552-1570

2024

Volltextzugriff (PDF)

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

Frontiers in oncology, 2018, Vol.8, p.508-508

2018

Volltextzugriff (PDF)

Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Blood cancer journal (New York), 2022-01, Vol.12 (1), p.8-8, Article 8

2022

Volltextzugriff (PDF)

Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome

Cell death & disease, 2024-05, Vol.15 (5), p.323-323, Article 323

2024

Volltextzugriff (PDF)

Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status

Frontiers in immunology, 2022-12, Vol.13, p.1073227-1073227

2022

Volltextzugriff (PDF)

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule

Molecular medicine (Cambridge, Mass.), 2013-01, Vol.19 (1), p.99-108

2013

Volltextzugriff (PDF)

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant

Bone marrow transplantation (Basingstoke), 2022-02, Vol.57 (2), p.312-314

2022

Volltextzugriff (PDF)

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma

Blood cancer journal (New York), 2024-07, Vol.14 (1), p.117-12, Article 117

2024

Volltextzugriff (PDF)

Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma

Frontiers in bioscience (Landmark. Print), 2020-01, Vol.25 (1), p.69-105

2020

Volltextzugriff (PDF)

Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers

Cancer medicine (Malden, MA), 2023-12, Vol.12 (23), p.21480-21489

2023

Volltextzugriff (PDF)

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study

Cancers, 2024-03, Vol.16 (6), p.1228

2024

Volltextzugriff (PDF)

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells

Nature communications, 2017-06, Vol.8 (1), p.15663-15663, Article 15663

2017

Volltextzugriff (PDF)

Nonconventional Management of a Hyperviscosity Syndrome Failing Plasma Exchange

Plasmatology, 2021-03, Vol.15

2021

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(182)
Mit Volltextzugriff
(166)

Publikationsform

Artikel
(186)
Berichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(94)
Humans
(90)
Hematology
(64)
Biological And Medical Sciences
(34)
Medical Sciences
(32)
Female
(29)
Male
(29)
Oncology
(29)
Multiple Myeloma
(28)
Middle Aged
(27)
Aged
(24)
Adult
(21)
Immunodeficiencies. Immunoglobulinopathies
(18)
Immunoglobulinopathies
(18)
Immunopathology
(18)
Multiple Myeloma - Immunology
(18)
Multiple Myeloma - Therapy
(17)
T-Lymphocytes - Immunology
(16)
Immunology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells

CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1

Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment

HIF-1α is over-expressed in leukemic cells from TP53 -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia

Molecular dynamics of targeting CD38 in multiple myeloma

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications

Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome

Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule

Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma

Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma

Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells

Nonconventional Management of a Hyperviscosity Syndrome Failing Plasma Exchange

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification

Suchergebnisse filtern